Shenzhen Anshi Biotechnology

Anshi Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-value, traditionally "undruggable" targets within oncology and metabolic diseases, with a particular emphasis on the RAS signaling pathway. Their lead programs include highly potent and selective KRAS G12D and G12V inhibitors designed to address significant unmet needs in pancreatic and colorectal cancers. By leveraging advanced structure-based drug design and medicinal chemistry, Anshi Biotechnology aims to deliver next-generation precision medicines to global markets.